HCPCS code S0078: Injection, fosphenytoin sodium, 750 mg PE

HCPCS code S0078 is a Level II Healthcare Common Procedure Coding System code that describes the injection of fosphenytoin sodium, 750 mg PE, used to bill Medicaid programs and commercial payers for acute anticonvulsant drug administration. Medicare Part B does not reimburse S078 under standard fee-for-service policy, which catches many billing teams off guard the first time a claim bounces.

This reference covers the code’s official descriptor, S-series classification, payer coverage rules, billing guidelines, IOCE status, ICD-10 crosswalk, and the documentation your team needs to defend medical necessity.

Found our content helpful?

Key Takeaways

HCPCS code S0078 describes injection, fosphenytoin sodium, 750 mg PE, a temporary Level II S-series code for non-Medicare payers

S078 is not reimbursable under standard Medicare Part B fee-for-service; it is used for Medicaid and commercial payer claims

The 750 mg PE unit refers to phenytoin equivalents, the standard dosing convention for fosphenytoin sodium

Claims must link a supported ICD-10 diagnosis (epilepsy, status epilepticus) to establish medical necessity

Pabau’s claims management software helps outpatient practices track S-series claim status across Medicaid and commercial payers

HCPCS code S0078: Quick reference

The table below summarises the key attributes of HCPCS code S0078 as maintained by the Centers for Medicare and Medicaid Services (CMS) and the Blue Cross Blue Shield Association, which administers S-series temporary codes.

Billing staff who understand medical billing workflows for injectable drugs know that confirming payer acceptance before claim submission saves significant rework. S0078 is active and billable for the applicable payer types listed above.

Full descriptor: What “750 mg PE” means

The official long descriptor for S0078 is “Injection, fosphenytoin sodium, 750 mg PE.” The short descriptor used in most billing systems is “Inj fosphenytoin sodium 750mg.” The abbreviation PE stands for phenytoin equivalents, the standard pharmacological convention for expressing fosphenytoin dosage.

Fosphenytoin is a prodrug of phenytoin. Because the body converts fosphenytoin into phenytoin after injection, clinicians and pharmacists dose it in phenytoin-equivalent units rather than fosphenytoin milligrams. One milligram PE is equivalent to one milligram of phenytoin. A 750 mg PE dose therefore delivers the same therapeutic phenytoin exposure as 750 mg of phenytoin itself.

Do not confuse S0078 with phenytoin injection codes. Fosphenytoin and phenytoin are distinct drugs with separate billing codes. Submitting a phenytoin code when fosphenytoin was administered creates a medical-necessity mismatch that invites denial or audit scrutiny.

S-series HCPCS code classification explained

S-series HCPCS codes are temporary Level II codes designated for use by non-Medicare payers. The BCBSA, not CMS, maintains and updates the S-series. This distinction matters for billing teams because CMS does not publish fee schedule rates for S-series codes through its standard Physician Fee Schedule lookup tool.

• Non-permanent status: S-series codes can be revised, deleted, or replaced during annual HCPCS updates without following the formal CMS rulemaking process that governs permanent codes.
• Non-Medicare scope: Medicare contractors are not obligated to accept S-series codes. Claims submitted to Medicare Part B with S0078 will be rejected under standard policy.
• Medicaid and commercial use: Most state Medicaid programs and the majority of commercial insurers that follow BCBSA coding conventions recognise S-series codes. Acceptance varies by state and plan contract.
• No CMS national payment rate: Reimbursement is set individually by each accepting payer. There is no federal fee schedule rate for S0078.

For practices that bill Medicaid, maintaining a clean separation between Medicare and Medicaid claim batches is essential. Proper claims management software can flag S-series codes automatically and route them away from Medicare claim files before submission.

Payer coverage: Medicaid, commercial, and Medicare

The most common billing error with HCPCS code S0078 is submitting it to Medicare Part B. S-series codes are by design excluded from standard Medicare fee-for-service reimbursement. Some Medicare Advantage plans write coverage for S-series codes into their plan-specific benefit designs, so always verify the specific plan’s coverage policy rather than assuming all Medicare products behave the same way.

Proactive insurance eligibility verification before the encounter prevents S078 from landing on a Medicare claim that has no path to payment. Running eligibility checks confirms which code sets the patient’s active plan accepts before the drug is administered.

Streamline Medicaid and commercial claims in one place

Pabau’s claims management tools help outpatient practices route S-series and other HCPCS codes to the right payer, flag Medicare-incompatible codes before submission, and track claim status across multiple payers from a single dashboard.

Book a demo

S078 billing guidelines

Coding fosphenytoin injection correctly means understanding how payers define the unit of service for S0078 and what modifier rules apply in outpatient settings. Submitting the wrong unit multiplier is the most common S078 billing mistake, resulting in either underpayment or overpayment recovery demands.

Unit of service

One unit of S0078 represents 750 mg PE of fosphenytoin sodium. If the patient received 1,500 mg PE, submit two units. Bill only the actual quantity administered per the physician order and administration record. Rounding up to the nearest 750 mg PE increment is not appropriate; only administered quantity counts.

Modifiers

Modifiers for S0078 depend on the payer’s specific billing guidelines. Common modifiers that may apply include JW (drug amount discarded) when a portion of a single-use vial is wasted. Some state Medicaid programs also require place-of-service modifiers for emergency department versus outpatient infusion settings. Verify modifier requirements with each payer’s provider manual before submitting.

Place of service

S0078 is most commonly billed for hospital outpatient, emergency department, and outpatient infusion centre encounters. Inpatient drug administration is typically bundled into the facility’s DRG payment and not separately billable with an HCPCS Level II code. Confirm the encounter setting before billing separately.

Reviewing your team’s clean claim submission checklist for drug injection codes before billing S0078 reduces the rate of preventable rejections. A clean claim for S0078 includes the correct unit count, a linked ICD-10 diagnosis, an NPI, and the applicable place-of-service code.

Reimbursement and IOCE status for S0078

Because S0078 is a non-Medicare code, it does not carry a CMS Ambulatory Payment Classification (APC) assignment or a national Medicare fee schedule rate. Reimbursement is set entirely by each individual payer’s drug fee schedule or the rate negotiated in your provider contract.

• Medicaid rates: Each state publishes its own Medicaid fee schedule for injectable drugs. Some states reimburse based on average wholesale price (AWP) minus a percentage discount; others use a fixed fee-for-service rate. Contact your state Medicaid program or review the published fee schedule annually.
• Commercial rates: Commercial payers that accept S0078 typically reimburse based on contracted rates or AWP benchmarks. Drug costs for fosphenytoin sodium (Cerebyx or generic equivalents) vary; ensure your contracted rate covers acquisition cost plus an appropriate dispensing/administration margin.
• IOCE status: The Integrated Outpatient Code Editor applies to Medicare outpatient claims. Because S0078 is not a Medicare code, it does not have an active IOCE status indicator for standard Medicare billing. If an outpatient Medicare Advantage plan accepts S0078, the applicable payment logic is plan-defined, not IOCE-governed.

Strong revenue cycle management practices require tracking S0078 reimbursements by payer to identify contracts that are underpaying relative to drug acquisition cost. Monitoring payment-per-unit trends across Medicaid and commercial claims helps surface contract renegotiation opportunities.

Associated ICD-10 diagnosis codes for S0078 claims

Every S0078 claim must link a supporting ICD-10-CM diagnosis code that establishes medical necessity for fosphenytoin administration. Fosphenytoin is an antiepileptic drug used to treat seizures and status epilepticus, so the applicable diagnoses are drawn from the epilepsy and seizure chapters of ICD-10-CM. The AAPC HCPCS Level II lookup tool provides crosswalk references for S-series codes alongside their commonly paired diagnoses.

Always use the most specific ICD-10-CM code the clinical documentation supports. Using R56.9 (unspecified convulsions) when the record clearly documents status epilepticus may invite a medical-necessity query from the payer. Consult your coding compliance team on medical billing compliance standards for specificity in diagnosis coding.

Related HCPCS codes for fosphenytoin and anticonvulsant drugs

Billing teams working in neurology, emergency medicine, or neurocritical care will encounter related codes alongside S0078. Understanding the differences prevents upcoding errors and supports accurate superbill documentation for anticonvulsant drug administration.

If S0078 is not accepted by a specific payer and fosphenytoin has no other applicable specific HCPCS code for that payer, J3490 (unclassified drugs) may be used as a billing alternative, accompanied by an invoice and drug identification. Check the NLM HCPCS Level II API for the most current code status and descriptors before billing any S-series alternative. Practices managing IV therapy and drug injection billing benefit from having robust denial management workflows in place, since unclassified drug claims attract higher scrutiny and slower adjudication.

Documentation requirements and medical necessity for S0078

Supporting documentation is the foundation of a defensible S0078 claim. Payers reviewing claims for injectable anticonvulsants will look for evidence that the drug was medically necessary, ordered by a licensed provider, and actually administered at the reported dose.

• Physician or prescriber order: A dated, signed order specifying fosphenytoin sodium, dose in mg PE, route of administration, and frequency. The order must appear in the medical record before the date of service or as an emergency verbal order with timely countersignature.
• Diagnosis linkage: The clinical record must document the seizure type or epilepsy diagnosis that supports the ICD-10 code billed. A note stating “seizure activity” without specifying type is insufficient for payers requiring code-level specificity.
• Administration record: The medication administration record (MAR) must confirm the drug name (fosphenytoin sodium), dose administered in mg PE, time, route, and administering clinician’s credentials.
• Clinical indication narrative: An emergency department or inpatient progress note documenting the clinical circumstances (active status epilepticus, failed first-line benzodiazepine therapy) strengthens medical necessity if the claim is audited.
• Waste documentation: If the JW modifier is applied for discarded drug, the MAR must document the amount wasted per applicable state and payer rules.

Practices that standardise their documentation workflows for drug injection claims reduce the frequency of additional-documentation requests (ADRs) from Medicaid and commercial payers. Track denial codes in medical billing for S-series claims specifically so patterns emerge quickly rather than appearing as scattered one-off rejections.

Conclusion

HCPCS code S0078 is a straightforward S-series code once billing teams understand its payer scope. The core rule is simple: Bill it to Medicaid and commercial payers, not to standard Medicare fee-for-service. Get the unit count right (750 mg PE per unit), link the correct epilepsy ICD-10 diagnosis, document the physician order and MAR, and your claim has a clean path to payment.

Managing injectable drug claims across multiple payer types is where claim routing, eligibility verification, and denial tracking earn their keep. Pabau’s claims management software helps outpatient practices keep S-series and other HCPCS drug codes in the right billing lane. To see how it fits your workflow, book a demo.

Continue your research

Need to understand how medical billing errors get caught and corrected? Denial management in healthcare covers the systematic approach to identifying, appealing, and preventing claim rejections.

Want a primer on what a clean claim looks like for injectable drugs? Clean claim submission explains the elements every drug injection claim needs to pass initial payer edits without a rejection.

Billing across Medicaid and commercial payers and need to track eligibility? Insurance eligibility verification walks through best practices for confirming payer-specific coverage before administering and billing high-cost injectable drugs.

Frequently Asked Questions